Spinal muscular atrophy, type II
MONDO:0009673Proximal spinal muscular atrophy type 2 (SMA2) is a chronic infantile form of proximal spinal muscular atrophy characterized by muscle weakness and hypotonia resulting from the degeneration and loss of the lower motor neurons in the spinal cord and the brain stem nuclei.
Also known as: Intermediate spinal muscular atrophy, SMA type 2, SMA type II, SMA-II, SMA2, chronic infantile spinal muscular atrophy, chronic spinal muscular atrophy, muscular atrophy, spinal, infantile chronic form
41 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
Could a zapping cap boost memory? small study tests brain stimulation for cognitive decline
Symptom relief Not yet recruitingThis pilot study will test whether a non-invasive brain stimulation technique called transcranial alternating current stimulation (tACS) can improve working memory in 30 adults with mild cognitive impairment or traumatic brain injury. Participants will receive low-level electrica…
Phase: NA • Sponsor: Sunnybrook Health Sciences Centre • Aim: Symptom relief
Last updated Jun 27, 2026 12:28 UTC
-
Horse power: new therapy hopes to improve movement in SMA children
Symptom relief Not yet recruitingThis study tests whether a special type of horseback physiotherapy can improve movement, posture, breathing, and quality of life in children with spinal muscular atrophy (SMA). Twenty children aged 2 to 9 years will receive both the horse therapy and standard physiotherapy in ran…
Phase: NA • Sponsor: Charles University, Czech Republic • Aim: Symptom relief
Last updated Jun 27, 2026 08:10 UTC
-
New study tracks Risdiplam's Real-World impact on spinal muscle atrophy
Knowledge-focused Not yet recruitingThis study will observe 30 children with type I or type II spinal muscle atrophy who are taking risdiplam. Researchers will track motor function improvements over 24 months using standard tests. The goal is to see how well the drug works in everyday medical practice.
Sponsor: Hoffmann-La Roche • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Gene therapy readiness check: new study maps virus immunity in muscle disease patients
Knowledge-focused Not yet recruitingThis study will test blood samples from 450 people aged 6 to 60 with inherited neuromuscular diseases to see if they have antibodies that could block gene therapy viruses (AAVs). The goal is to understand how common these antibodies are and which patients might be good candidates…
Phase: NA • Sponsor: Genethon • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC